Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Shares Outstanding (Diluted Average) (2018 - 2026)

Denali Therapeutics has reported Shares Outstanding (Diluted Average) over the past 8 years, most recently at $172.6 million for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 4.97% to $172.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $172.6 million through Dec 2025, up 4.97% year-over-year, with the annual reading at $172.6 million for FY2025, 4.97% up from the prior year.
  • Shares Outstanding (Diluted Average) was $172.6 million for Q4 2025 at Denali Therapeutics, roughly flat from $172.4 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $172.6 million in Q4 2025 and troughed at $120.9 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $137.5 million (2023), against an average of $143.6 million.
  • Year-over-year, Shares Outstanding (Diluted Average) increased 1.08% in 2022 and then grew 23.11% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $121.5 million in 2021, then increased by 3.3% to $125.5 million in 2022, then rose by 9.43% to $137.4 million in 2023, then increased by 19.73% to $164.5 million in 2024, then rose by 4.97% to $172.6 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Shares Outstanding (Diluted Average) are $172.6 million (Q4 2025), $172.4 million (Q3 2025), and $171.4 million (Q2 2025).